Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard
Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard
Haemagglutination-inhibition (HI) and virus neutralisation (VN) assays are used to evaluate immunogenicity of pandemic H1N1 vaccines; however these bioassays are poorly standardised leading to inter-laboratory variation. A candidate International Standard (IS) for antibody to H1N1 pdm virus (09/194) was prepared from pooled sera of subjects who had either recovered from H1N1 pdm infection or who had been immunised with an adjuvanted subunit vaccine prepared from reassortant virus NYMC X-179A (derived from A/California/7/2009 virus). Ten laboratories from seven countries tested the candidate IS, 09/194 and a panel of human sera by HI and VN using the A/California/7/2009 virus (six laboratories) and/or the reassortant virus NYMC X-179A (ten laboratories). As expected, the inter-laboratory variability for HI and VN assay results was high. For results of antibody tests to NYMC X-179A, the % geometric coefficient of variation (%GCV) for 09/194 between laboratories was 83% for HI and 192% for VN. For tests of all sera, the median %GCV ranged from 95 to 345% for HI (80-fold variation) and 204 to 383% for VN (109-fold variation), but for the titres relative to 09/194 the median %GCV was much reduced (HI 34-231%; VN 44-214%). For tests of antibody to the A/California/7/2009 wild type virus there were similar reductions in %GCV when 09/194 was used. These results suggest that 09/194 will be of use to standardise assays of antibody to A/California/7/2009 vaccine and 09/194 has now been established by WHO as an IS for antibody to A/California/7/2009 with an assigned potency of 1300 IU per ml.
influenza, serology, haemagglutination–inhibition, neutralisation, antibody standard, pandemic
210-217
Wood, John M.
901bec4f-a57d-46d2-8ce6-0e2fd3347556
Major, Diane
8e21944a-dfd0-4a93-b8f6-54376b951484
Heath, Alan
c5632721-b3a6-40ea-9c9a-9303f84dad32
Newman, Robert W.
dc48f3ed-1916-495c-b93f-6f72d7f63f36
Höschler, Katja
9f8b0f72-2b73-4e47-98d2-56af6ad803df
Stephenson, Iain
494ddca3-8e9e-44fd-ab1e-4fe620842bd0
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
Katz, Jacqueline M.
23eb5479-e7d4-4809-b2f3-ed2804956550
Zambon, Maria C.
3d232c1d-ac62-48e5-a880-c5149024fd32
5 January 2012
Wood, John M.
901bec4f-a57d-46d2-8ce6-0e2fd3347556
Major, Diane
8e21944a-dfd0-4a93-b8f6-54376b951484
Heath, Alan
c5632721-b3a6-40ea-9c9a-9303f84dad32
Newman, Robert W.
dc48f3ed-1916-495c-b93f-6f72d7f63f36
Höschler, Katja
9f8b0f72-2b73-4e47-98d2-56af6ad803df
Stephenson, Iain
494ddca3-8e9e-44fd-ab1e-4fe620842bd0
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
Katz, Jacqueline M.
23eb5479-e7d4-4809-b2f3-ed2804956550
Zambon, Maria C.
3d232c1d-ac62-48e5-a880-c5149024fd32
Wood, John M., Major, Diane, Heath, Alan, Newman, Robert W., Höschler, Katja, Stephenson, Iain, Clark, Tristan, Katz, Jacqueline M. and Zambon, Maria C.
(2012)
Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.
Vaccine, 30 (2), .
(doi:10.1016/j.vaccine.2011.11.019).
(PMID:22100887)
Abstract
Haemagglutination-inhibition (HI) and virus neutralisation (VN) assays are used to evaluate immunogenicity of pandemic H1N1 vaccines; however these bioassays are poorly standardised leading to inter-laboratory variation. A candidate International Standard (IS) for antibody to H1N1 pdm virus (09/194) was prepared from pooled sera of subjects who had either recovered from H1N1 pdm infection or who had been immunised with an adjuvanted subunit vaccine prepared from reassortant virus NYMC X-179A (derived from A/California/7/2009 virus). Ten laboratories from seven countries tested the candidate IS, 09/194 and a panel of human sera by HI and VN using the A/California/7/2009 virus (six laboratories) and/or the reassortant virus NYMC X-179A (ten laboratories). As expected, the inter-laboratory variability for HI and VN assay results was high. For results of antibody tests to NYMC X-179A, the % geometric coefficient of variation (%GCV) for 09/194 between laboratories was 83% for HI and 192% for VN. For tests of all sera, the median %GCV ranged from 95 to 345% for HI (80-fold variation) and 204 to 383% for VN (109-fold variation), but for the titres relative to 09/194 the median %GCV was much reduced (HI 34-231%; VN 44-214%). For tests of antibody to the A/California/7/2009 wild type virus there were similar reductions in %GCV when 09/194 was used. These results suggest that 09/194 will be of use to standardise assays of antibody to A/California/7/2009 vaccine and 09/194 has now been established by WHO as an IS for antibody to A/California/7/2009 with an assigned potency of 1300 IU per ml.
This record has no associated files available for download.
More information
Accepted/In Press date: 5 November 2011
e-pub ahead of print date: 17 November 2011
Published date: 5 January 2012
Keywords:
influenza, serology, haemagglutination–inhibition, neutralisation, antibody standard, pandemic
Organisations:
Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 386396
URI: http://eprints.soton.ac.uk/id/eprint/386396
PURE UUID: 0b482bfa-cd71-40c8-b5f3-11cb3d0a2e9e
Catalogue record
Date deposited: 01 Feb 2016 12:14
Last modified: 15 Mar 2024 03:49
Export record
Altmetrics
Contributors
Author:
John M. Wood
Author:
Diane Major
Author:
Alan Heath
Author:
Robert W. Newman
Author:
Katja Höschler
Author:
Iain Stephenson
Author:
Jacqueline M. Katz
Author:
Maria C. Zambon
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics